Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
Sell
-54,800
Closed -$3.67M 3270
2024
Q3
$3.67M Hold
54,800
0.01% 1256
2024
Q2
$6.21M Hold
54,800
0.01% 912
2024
Q1
$7.6M Buy
54,800
+50,700
+1,237% +$6.37M 0.02% 765
2023
Q4
$509K Sell
4,100
-20,100
-83% -$2.05M ﹤0.01% 2451
2023
Q3
$2.26M Buy
+24,200
New +$2.73M 0.01% 1302
2022
Q1
Sell
-24,000
Closed -$3.22M 3116
2021
Q4
$3.22M Sell
24,000
-6,000
-20% -$862K 0.01% 1526
2021
Q3
$4.1M Sell
30,000
-1,200
-4% -$151K 0.01% 1379
2021
Q2
$3.33M Buy
31,200
+15,200
+95% +$1.46M 0.01% 1472
2021
Q1
$1.44M Sell
16,000
-118,800
-88% -$11.2M ﹤0.01% 1983
2020
Q4
$12.5M Buy
134,800
+74,400
+123% +$6.64M 0.04% 521
2020
Q3
$6.22M Sell
60,400
-20,000
-25% -$2.09M 0.02% 709
2020
Q2
$8.15M Sell
80,400
-8,800
-10% -$787K 0.04% 458
2020
Q1
$6M Buy
89,200
+43,600
+96% +$2.71M 0.05% 424
2019
Q4
$2.49M Buy
45,600
+13,600
+43% +$645K 0.01% 1417
2019
Q3
$1.19M Buy
32,000
+20,000
+167% +$777K ﹤0.01% 1829
2019
Q2
$450K Buy
+12,000
New +$377K ﹤0.01% 2583
2018
Q2
Sell
-215,600
Closed -$4M 3387
2018
Q1
$4M Buy
+215,600
New +$3.19M 0.01% 1083
2017
Q3
Sell
-44,000
Closed -$805K 2826
2017
Q2
$805K Sell
44,000
-51,200
-54% -$946K ﹤0.01% 2034
2017
Q1
$2.02M Buy
+95,200
New +$1.86M 0.01% 1449

Other funds holding DXCM

John Overdeck's DXCM Position: Q2 2026 in Review

John Overdeck reduced its DexCom (DXCM) stake by 96% in Q2 2026, selling an estimated $71.2M and leaving 46,697 shares worth $3.15M. The position accounts for ﹤0.01% of the portfolio, ranked #2578.

John Overdeck first reported a position in DXCM in Q2 2013 and has held it in 36 quarters since. The position peaked at $193M in Q4 2021. 966 funds tracked by Wall St. Rank hold DXCM as of Q2 2026.

  • John Overdeck held 46,697 shares of DexCom worth $3.15M as of Q2 2026.
  • John Overdeck sold 1,068,251 DexCom shares in Q2 2026, an estimated $71.2M.
  • DexCom made up ﹤0.01% of John Overdeck's portfolio in Q2 2026, its #2578 holding.
  • John Overdeck first reported a position in DexCom in Q2 2013 and has held it in 36 quarters since.
  • John Overdeck's DexCom position peaked at $193M in Q4 2021.
  • 966 funds tracked by Wall St. Rank held DexCom as of Q2 2026.

Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.